FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN THE EFFECTIVE BENEFICIARIES OF THE SHARES Filed under Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
|||||||||||||||||||||||||
|
Table II – Beneficial ownership derivative securities (for exampleputs, calls, warrants, options, convertible securities)
(for exampleputs, calls, warrants, options, convertible securities)
1. Title of derivative title |
2. Conversion or exercise price of the derivative security |
3. Transaction date (month/day/year) |
3A. Deemed execution date, if applicable (month/day/year) |
4. Transaction code |
5. Number of derivative securities acquired (A) or sold (D) |
6. Exercise date and expiry date |
7. Title and amount of the securities underlying the derivative securities |
8. Price of derivative securities |
9. Number of derivative securities beneficially owned as a result of reported transactions |
10. Form of ownership of derivative securities: direct (D) or indirect (I) |
11. Nature of Indirect Beneficial Ownership |
Coded |
V |
(A) |
(D) |
Exercise date |
Expiration date |
Title |
Amount or number of shares |
Reporting owners
Name/address of declaring owner | Relationships | |||
Director |
10% Owner |
Officer |
Other |
|
Klein Pamela M. |
X |
Signatures
/s/ Darlene Deptula-Hicks, practicing lawyer |
2022-06-22 |
**Signature of declaring person |
Date |
Explanation of answers:
If the form is completed by several declarants, see |
|
Section 5(b)(v). |
(**) Intentional misrepresentation or omission of facts are federal criminal offenses. See |
18 USC 1001 and 15 USC 78ff(a). |
(1) |
These options were granted as part of the Issuer’s compensation program for non-employee directors. |
(2) |
Shares under the award will vest in 12 equal monthly installments over a one-year period through June 16, 2023, subject to the reporting person’s continued service as a director of the company. Note: Submit three copies of this form, one of which must be manually signed. If space is insufficient, See
Instruction 6 for the procedure. Potential individuals who need to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Disclaimer F-star Therapeutics Inc. published this content on June 22, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, onJun 23, 2022 04:34:07 UTC
.
|
|
|
|
Analyst Recommendations on F-STAR THERAPEUTICS, INC.
|
|
95.8%
|
||||
|
||||
F-star Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Short term | Middle term | ||
Long term | Tendencies | Bullish | Neutral |
Neutral
Please enable JavaScript in your browser settings to use dynamic graphics. ![]() Sale |
|
To buy | Medium consensus |
TO BUY | Number of analysts |
seven | Last closing price |
$3.98 | Average target price |
$25.71 | Average Spread / Target |
Please enable JavaScript in your browser settings to use dynamic graphics.